FACG

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Retrieved on: 
수요일, 4월 10, 2024
Oncology, Health, Genetics, Other Health, Other Science, Science, Biotechnology, Steps, Education, Risk, Esophageal cancer, ECAN, CPI, Research, Hepatology, GI, Disease, Patient, Physician, Northwestern University, Diagnosis, GERD, Castle, FACP, Division, Gastroesophageal reflux disease, FACG, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.
  • The Company is proud to continue its ongoing collaboration with the Esophageal Cancer Action Network (ECAN), Gastro Broadcast podcast and EndoscopyNow to help advance esophageal cancer research, prevention, education and advocacy.
  • “Unfortunately, esophageal cancer is often detected at its late stages and the five-year survival rate of esophageal cancer patients is less than 20%,”1 said Emmanuel Gorospe, M.D., MPH, CPI, FACP, FACG, FASGE, GI Medical Director at Castle Biosciences.
  • TissueCypher® is Castle’s prognostic risk-stratification test designed to predict progression to high-grade dysplasia or esophageal cancer.

Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Retrieved on: 
목요일, 3월 28, 2024
Washington Convention Center, Walter, FACG, FACP, AGAF, University, IGG, DDW, Gastroenterology, IBS, RFF

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC.

Key Points: 
  • IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC.
  • DDW is renowned as the world's premier scientific and clinical meeting for digestive disease health care professionals.
  • "We are excited that our technology will be prominently featured in a presentation at this year's DDW conference," said CEO Zack Irani.
  • "The forthcoming presentation marks a significant milestone, contributing valuable data to the growing clinical evidence supporting the efficacy of the InFoods IBS technology."

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Retrieved on: 
일요일, 2월 4, 2024
ALP, AGAF, IBD, Ascending cholangitis, Liver failure, Pharmacokinetics, SAN, Washington State University, Inflammation, Fibrosis, Cirrhosis, Itch, PSC, Ursodeoxycholic acid, MRI, Telephone, Magnetic resonance imaging, Inflammatory bowel disease, Patient, Safety, FDA, EMA, FACP, Disease, IPF, SAE, FRCP, ELF, Week, Therapy, Conference call, Alkaline phosphatase, Interest, UDCA, FACG, University, Webcast, Liver, Primary sclerosing cholangitis, Plasma, Liver disease, Conference, Medical imaging

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. There was no dose relationship for adverse events. Pruritus and cholangitis occurred less frequently on bexotegrast than on placebo.

Key Points: 
  • The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging (MRI) of the liver.
  • In addition, MRI imaging continued to show evidence of improved hepatocyte function and bile flow with bexotegrast at the 320 mg dose relative to placebo.
  • INTEGRIS-PSC is a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a trial evaluating bexotegrast at once-daily oral doses of 40 mg, 80 mg, 160 mg, 320 mg or placebo for 12 weeks in 121 patients with PSC.
  • The 320 mg group enrolled 27 patients in the active arm and added 9 new patients to the pooled placebo arm.

US Digestive Health Expands Surgical Services with New Provider and Practice Location in York, PA

Retrieved on: 
목요일, 11월 16, 2023
FACG, Elective surgery, Physician, Patient, Hospital

Dr. Evans is highly skilled surgeon and will continue to offer his General Surgical services and procedures while advancing his endoscopic practice with the launch of the new USDH location in York.

Key Points: 
  • Dr. Evans is highly skilled surgeon and will continue to offer his General Surgical services and procedures while advancing his endoscopic practice with the launch of the new USDH location in York.
  • "Our mission is and always has been to expand access to high-quality GI care," said Jerry Tillinger, CEO of US Digestive Health.
  • The practice has continued its rapid expansion of services throughout Pennsylvania and Delaware, making it one of the nation's leading and most trusted providers of digestive health care.
  • "I'm excited to join the US Digestive Health team at our newest location in York," said Dr. Evans.

Velocity aggressively expands MASH/MASLD capabilities with latest site acquisitions

Retrieved on: 
수요일, 10월 25, 2023
Potsdam Institute for Climate Impact Research, Gastroenterology, FDA, Research, Oregon Health & Science University, United States Department of the Air Force, Obesity, General Social Care Council, Prevalence, Biological therapy for inflammatory bowel disease, Liver disease, Paulinum (University of Leipzig), ChromeOS, CPI, Tufts University School of Medicine, AGAF, Growth, Disease, St George's Hospital, NASH, University, KOL, Internal medicine, Icahn School of Medicine at Mount Sinai, Air force, Brooke Army Medical Center, DURHAM, FACP, FACG, Hepatology, Veteran, Patient, MASH, Dietary supplement, Pharmaceutical industry, Medical device, Nursing, MD, Velocity

DURHAM N.C., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease).

Key Points: 
  • Velocity is a major player in this space with 23 sites capable of performing MASH/MASLD studies globally.
  • With the two recent site acquisitions, Velocity adds two internationally renowned researchers and key opinion leaders (KOL) in liver disease research as principal investigators, Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, who join Roland Kuchta, MD, in Germany.
  • Dr. Gunn commented, “We are fully prepared to make Velocity the first-choice site network for liver disease clinical trials worldwide.
  • Velocity has over 80 locations globally and access to more than 220 principal investigators and one million patients.

ACG 2023 Presentations for REBYOTA® (fecal microbiota, live – jslm) Explore Association Between Gut Microbiome Composition and Health-Related Quality of Life and Evaluate Efficacy and Safety in Older Patients With Comorbidities

Retrieved on: 
월요일, 10월 23, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Clostridioides difficile infection, Yale School of Medicine, PUNCH, GI, Patient, American College, Food, Gammaproteobacteria, ACG, MD, Clostridioides difficile, Atrial fibrillation, Coronary artery disease, Safety, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bacteroidales, Microbiota, Multimedia, Life, Chronic kidney disease, Ferring Pharmaceuticals, AGAF, Recurrence, OLS, Bacteria, Kidney disease, Kidney, Overalls, Irritable bowel syndrome, FACG, Inflammatory bowel disease, Gastroesophageal reflux disease, Pharmaceutical industry, Bacilli

Patients were categorized as improved if Cdiff32 scores improved 10 points or more from baseline to week 8.

Key Points: 
  • Patients were categorized as improved if Cdiff32 scores improved 10 points or more from baseline to week 8.
  • The average microbiome profiles were then compared between baseline and week 8 within the improved and unchanged groups, respectively.
  • The analysis found that the quartile with the highest Cdiff32 score showed a significantly different microbiome composition from most other groups with lower scores.
  • “Seeing efficacy and safety consistent with previous clinical trials of REBYOTA among these higher-risk patients is encouraging.”

CIBC Innovation Banking Provides Senior Credit Facilities to Medisolv

Retrieved on: 
수요일, 7월 12, 2023
Technology, Venture Capital, Fintech, Banking, Health Technology, Professional Services, Software, Practice Management, Health, Health care, FACG, Hospital, BVP

CIBC Innovation Banking announced today that it has provided Senior Credit Facilities to support BVP Forge’s strategic investment and fund working capital in Medisolv, a leading healthcare quality management platform.

Key Points: 
  • CIBC Innovation Banking announced today that it has provided Senior Credit Facilities to support BVP Forge’s strategic investment and fund working capital in Medisolv, a leading healthcare quality management platform.
  • Medisolv helps improve the quality of patient care and provider performance by enabling users with the latest technologies to aggregate data across a wide variety of clinical and financial sources.
  • The platform is used by thousands of hospitals and healthcare providers across the U.S.
    “We are delighted to support Medisolv’s mission to advance towards a value-based healthcare delivery and payments model,” said Joe Hammer, Co-Head Life Science and Healthcare, CIBC Innovation Banking.
  • “CIBC Innovation Banking's team industry expertise will be invaluable as we partner with BVP Forge to advance our efforts.”

American College of Gastroenterology and American Gastroenterological Association Invest in Oshi Health to Accelerate Adoption of Hybrid Digestive Health Care

Retrieved on: 
화요일, 6월 13, 2023
Insurance, University of California, San Diego Performance-Based Skills Assessment, FACG, Partnership, University, Health policy, Diabetes, American Gastroenterological Association, Workplace, Quality of life, Human, MBA, Science, Nature Reviews Gastroenterology & Hepatology, AGAF, AGA, Patient, AHIP, Outline of health sciences, DHPA, System, American College of Gastroenterology, American College, Treasurer, Society, GI, ACG, Nursing, Pharmaceutical industry, Oshi, MD, Gastroenterology

PORTLAND, Ore., June 13, 2023 (GLOBE NEWSWIRE) -- AHIP 2023 CONFERENCE -- Oshi Health today announced strategic investments by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) GI Opportunity Fund .

Key Points: 
  • PORTLAND, Ore., June 13, 2023 (GLOBE NEWSWIRE) -- AHIP 2023 CONFERENCE -- Oshi Health today announced strategic investments by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) GI Opportunity Fund .
  • As part of the arrangement, both the ACG and AGA have made strategic financial investments in Oshi Health as an illustration of the importance of providing patients access to the evidence-based, multidisciplinary care offered by Oshi.
  • “As an organization, ACG aims to empower gastroenterologists to embrace the science supporting new guidelines and how to integrate them into clinical practice.
  • Lack of access to multidisciplinary care and support between traditional GI care visits can result in poor patient outcomes and avoidable emergency services.

GI Alliance Expands Washington Market with Digestive Health Consultants

Retrieved on: 
금요일, 6월 2, 2023
Yee, FACP, FACG, WAGI, Partnership, AGAF, GI, Patient, Physician, Nursing

DALLAS, June 2, 2023 /PRNewswire/ -- GI Alliance , the nation's premier gastroenterology management organization, is excited to announce a partnership with Digestive Health Consultants, expanding GI Alliance's presence in Washington.

Key Points: 
  • DALLAS, June 2, 2023 /PRNewswire/ -- GI Alliance , the nation's premier gastroenterology management organization, is excited to announce a partnership with Digestive Health Consultants, expanding GI Alliance's presence in Washington.
  • "Digestive Health Consultants is a natural fit with our existing Washington Gastroenterology locations," said James Weber, M.D., CEO of GI Alliance.
  • Digestive Health Consultants joins GI Alliance's existing Washington-based practice, Washington Gastroenterology (WAGI), bringing the total physician count to thirty-eight in Washington.
  • "Digestive Health Consultants is a natural fit with our existing Washington Gastroenterology locations," said James Weber, M.D., CEO of GI Alliance.

Medisolv Receives Strategic Investment from BVP Forge

Retrieved on: 
월요일, 5월 22, 2023
Data Management, Health, Technology, Hospitals, Managed Care, Software, General Health, Heart, FACG, Intelligence, Multimedia, IP, Hospital, Acquisition, Investment, Lincoln International, Growth, BVP, Management, MD

Medisolv Inc. , a leader in healthcare quality data measurement and reporting solutions, announced today that BVP Forge has completed a strategic investment in the company to accelerate its growth.

Key Points: 
  • Medisolv Inc. , a leader in healthcare quality data measurement and reporting solutions, announced today that BVP Forge has completed a strategic investment in the company to accelerate its growth.
  • “We were attracted to BVP Forge given their one-of-a-kind model that combines on-the-ground operational scaling support with the growth resources of Bessemer Venture Partners.
  • BVP Forge will also provide Medisolv access to the growth IP, talent network, and resources of Bessemer Venture Partners, which has decades of experience scaling healthcare and technology companies into market leaders.
  • “We are highly impressed with Medisolv’s mission-centric culture and demonstrated track record of consistent, profitable growth,” said Brian Cramer, BVP Forge Operating Partner.